Publications by authors named "Muhammad Hussain Ahmadvand"
Background: The pRESET stent retriever is a self-expanding nitinol stent designed for mechanical thrombectomy in cases of large vessel occlusion during acute ischemic stroke. This systematic review and meta-analysis synthesize the available evidence on the safety and efficacy of the pRESET device.
Methods: This is a systematic review and meta-analysis study conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Role of Statins in the Clinical and Radiologic Outcomes of Patients with Unruptured Intracranial Aneurysm Undergoing Microsurgery or Endovascular Treatment: A Systematic Review and Meta-Analysis.
World Neurosurg
December 2024
Article Synopsis
- Statin pretreatment in patients undergoing endovascular treatment for intracranial aneurysms does not significantly improve the outcomes like complete occlusion rates, but it has some notable effects.
- Statins were associated with an increased risk of ischemic stroke, yet they also reduced the risk of hemorrhagic complications and the likelihood of in-stent stenosis.
- Further research is necessary to better understand the balance of benefits and risks of statin use in these patients.
Background: Recent favorable cohort studies on endovascular therapy for ischemic stroke have predominantly utilized NeVa thrombectomy (NeVa stent retrievers. We carried out a systematic review and meta-analysis to investigate the efficacy and safety of this second-generation stent retriever in acute ischemic stroke patients.
Method: We conducted the study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Background: Dendritic cell (DC) vaccines show promise for glioma treatment, but optimal use remains uncertain. This meta-analysis examined DC vaccine efficacy and safety for gliomas.
Methods: This systematic review and meta-analysis study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
Neurosurg Rev
August 2024
Article Synopsis
- * The combination treatment leads to modest improvements in overall survival (OS) rates, with 2-year OS at 39% for those receiving bevacizumab versus 20% for standard therapy alone.
- * Despite potential benefits, the treatment is associated with a 62% incidence of adverse events, including significant complications like fatigue and CNS hemorrhage, highlighting the need for careful patient
Melanoma brain metastases present a major challenge in cancer treatment and reduce overall survival despite advances in managing primary melanoma. Immune checkpoint inhibitors (ICIs) that target PD-1/PD-L1 pathways have shown promise in treating advanced melanoma, but their efficacy for melanoma brain metastases is debated. This systematic review and meta-analysis summarize evidence on anti-PD-1/PD-L1 inhibitors for melanoma brain metastases.
View Article and Find Full Text PDFSafety and efficacy of flow redirection endoluminal device (FRED) for treatment of intracranial aneurysm; A systematic review and meta-analysis.
Neuroradiol J
August 2024
Background: Previous research has shown promising results for treating intracranial aneurysms (IAs) with a flow redirection endoluminal device (FRED). In this systematic review and meta-analysis, we aimed to assess the safety and efficacy of this device by providing pooled estimates using the data from previous studies.
Methods: A systematic literature search of Web of Sciences, PubMed, Scopus, and Embase was performed until October 8th, 2023.
Background: Dabrafenib and trametinib represent targeted therapy options under investigation for treatment of gliomas harboring BRAF V600 mutations. We systematically reviewed the literature and conducted meta-analyses to assess the efficacy and safety of these agents.
Methods: PubMed, Embase, and Scopus were searched from inception to September 2023 for studies examining dabrafenib and/or trametinib for gliomas.